BIOMAT Database Logo BIOMAT Database Logo

Benefits of isoniazid preventive therapy. 1996

D N Rose

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008017 Life Expectancy Based on known statistical data, the number of years which any person of a given age may reasonably be expected to live. Life Extension,Years of Potential Life Lost,Expectancies, Life,Expectancy, Life,Life Expectancies
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses

Related Publications

D N Rose
Isoniazid preventive therapy.
April 1996, Archives of internal medicine,
D N Rose
Isoniazid preventive therapy in areas of high isoniazid resistance.
January 1995, Archives of internal medicine,
D N Rose
Isoniazid preventive therapy in areas of high isoniazid resistance.
March 1996, Archives of internal medicine,
D N Rose
Toxicity associated with isoniazid preventive therapy.
December 1999, JAMA,
D N Rose
Isoniazid preventive therapy: Retrospect and prospect.
June 1980, The American review of respiratory disease,
D N Rose
Acute isoniazid neurotoxicity during preventive therapy.
February 2000, Critical care medicine,
D N Rose
Isoniazid preventive therapy in HIV infection.
May 2011, Lancet (London, England),
D N Rose
Hyperglycaemia induced by isoniazid preventive therapy.
January 2018, Journal of family medicine and primary care,
D N Rose
HIV, Pregnancy, and Isoniazid Preventive Therapy.
March 2020, The New England journal of medicine,
D N Rose
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
November 2016, AIDS (London, England),
Copied contents to your clipboard!